Big Money Spent On Liquid Biopsy Technology In 2021

Deal-making and financing activities are on the rise for liquid biopsy diagnostic products in 2021 despite questions remaining around whether the technology can unseat standard-of-care biomarker and imaging tests.

liquid biopsy
• Source: Alamy

In May, there were two prominent acquisitions that centered on liquid biopsy technology. Labcorp agreed to pay $150m in cash for Myriad Genetics, Inc.’s autoimmune business; while NeoGenomics, Inc. acquired liquid biopsy company Inivata Ltd. for $390m to expand its growing cancer testing capabilities.

Labcorp has expanded its rheumatoid arthritis diagnostics line-up by acquiring the Vectra rheumatoid arthritis assay from Myriad Genetics. Myriad is...

More from Deal-Making

More from In Vivo